-+ 0.00%
-+ 0.00%
-+ 0.00%

20/20 Biolabs Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $380.216K Miss $640.000K Estimate

Benzinga·11/16/2026 22:46:09
Listen to the news
20/20 Biolabs (NASDAQ:AIDX) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 29.41 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $380.216 thousand which missed the analyst consensus estimate of $640.000 thousand by 40.59 percent. This is a 9.03 percent decrease over sales of $417.979 thousand the same period last year.